WO2006051805A1 - インターフェロンα変異蛋白質とその用途 - Google Patents
インターフェロンα変異蛋白質とその用途 Download PDFInfo
- Publication number
- WO2006051805A1 WO2006051805A1 PCT/JP2005/020514 JP2005020514W WO2006051805A1 WO 2006051805 A1 WO2006051805 A1 WO 2006051805A1 JP 2005020514 W JP2005020514 W JP 2005020514W WO 2006051805 A1 WO2006051805 A1 WO 2006051805A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- residue
- ifn
- amino acid
- mutant
- mutant protein
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the present invention relates to a novel interferon mutant protein, and more particularly to a human interferon mutant subtype 8 mutant protein and a susceptibility disease agent comprising the same.
- IFN a human interferon ⁇ subtype ⁇ 8
- IFN a 8 human interferon ⁇ subtype ⁇ 8
- Subtypes a 2a and a 2b hereinafter also referred to as “IFN a 2a” and “IFN a 2b”, respectively
- IFN a 2a subtype ⁇ 8
- IFN a 2b subtypes of IFN a It has been reported.
- IFN 8 is more than other subtypes of IFN It exhibits extremely high antiviral activity, and in addition, Yanai Y, Horie S, Yamamoto K, Yamauchi H, Ikegami H ), Kurimoto M, Kitamura T, G According to Journal of Interferon & Cytokine Research, 21st, No. 12, 1, 129 to 1, 136, 2001, IFN ct 8 is It exhibits superior antitumor activity against kidney cancer than other IFN ct subtypes.
- an object of the present invention is to provide a sensitive disease agent comprising an IFN a mutant protein, which is superior in antiviral action and antitumor activity as compared with conventional IFN ⁇ , as an active ingredient. It is.
- the 145th arginine residue in the amino acid sequence of IFN a 8 shown in any one of SEQ ID NOS: 1 to 3 in the sequence listing is an isoleucine residue or leucine residue.
- an IFN a variant protein in which the 146th alanine residue is converted to a asparagine residue or a serine residue and the 149th methionine residue is converted to a tyrosine residue is converted into a wild-type IFN a 8 It was found that the activity was significantly higher than that.
- the lysine-mutated mutant protein produced by converting one or more lysine residues in the amino acid sequence of the above IFN ⁇ -mutated protein to other amino acid residues binds to a water-soluble polymer.
- the bioactive complex is combined with a conventional water-soluble polymer, it has been found to have extremely high activity compared to the IFN a preparation, and the present invention has been completed.
- the present invention relates to the amino acid sequence of human interferon subtype 8 shown in any one of SEQ ID NOS: 1 to 3 in the sequence listing, and the 145th arginine residue is replaced with a leucine residue.
- a mutant protein comprising an amino acid sequence in which an isoleucine residue or a palin residue, a 146th alanine residue is converted to a wasparagine residue or a serine residue, and a 149th methionine residue is converted to a tyrosine residue
- the said subject is solved by providing the sensitive disease agent which comprises it as an active ingredient.
- the IFN a muteins used in the present invention are wild-type IFN a 8, ie, IFN ⁇ 8a (SEQ ID NO: 1 in the sequence listing), IFN ct 8b (SEQ ID NO: 2 in the sequence listing) and IFN a 8c.
- IFN ct mutant protein used in the present invention can be obtained by a conventional genetic engineering technique.
- the protein is expressed by a phage display method, etc., and screening is performed using a combination of an antibody against IFN, a banning method using a receptor protein, an enzyme immunization method, a bioassay method, etc., so that it is more active than IFN a 8.
- An enhanced IFN a variant protein can be obtained.
- the phage display method is an extremely useful means because it can comprehensively screen for mutant protein candidates.
- IFN a mutant protein used in the present invention Pierre one error 'defense (Piehler, J) (THE. Di Yananore. O blanking. Bio Logica Honoré. Chemistry, (Th e journal of Biological Che mistry), ⁇ 275 ⁇ , No. 51, pages 40425 to 40433, 2000), etc., in the amino acid sequence of IFN a 8, which is said to be involved in binding to IFN a receptor type 2, ie, , 30, 33, 145, 146, 149 and 150 amino acid residues are converted into random amino acid residues, and a comprehensive mutant is prepared by the above-mentioned genetic engineering technique to produce a suitable mutant protein.
- the 145th arginine residue is an isoleucine residue, leucine residue or valine residue
- the 146th alanine residue is an asparagine residue or a serine residue
- 149th methionine residue The those that have been converted into tyrosine residues.
- the IFNa mutant protein in which the amino acid residues at positions 145, 146, and 149 are converted as described above has markedly improved IFNa activity and is advantageously used as the IFNa mutant protein of the present invention.
- IFN preparations are inferior in the body, it may be advantageous to administer a biologically active complex bound with a water-soluble polymer to a living body.
- IFNs may have binding positions that, when bound to water-soluble polymers, can impair their activity due to steric hindrance. Therefore, the water-soluble polymer of IFN Mutant proteins whose binding positions are limited to positions that do not impair the activity are advantageously used in the present invention.
- the binding position of the protein with the water-soluble polymer is selected from the N-terminal or lysine residue.
- lysine-converted mutant protein in which one or more lysine residues have been converted to other amino acid residues
- lysine-converted mutant protein has an appropriate binding. It is possible to limit the bonding position with the water-soluble polymer at the position.
- lysine residues are present at the 31st, 46th, 50th, 71th, 122th, 134th, 135th, 160th, 163rd and 165th positions, and these positions are randomly selected.
- a lysine conversion mutant protein suitable for binding to a water-soluble polymer by substituting an amino acid residue and screening the lysine conversion mutant protein retaining the activity by the above-described genetic engineering technique. it can.
- the present inventors convert all lysine residues of the IFNa mutant protein of the present invention to other amino acid residues, the binding efficiency with the water-soluble polymer is extremely reduced. Therefore, it is desirable to preserve at least one lysine residue, and the lysine residue to be preserved is one of the 31st and 134th lysine residues. The knowledge that this is preferable is obtained.
- the lysine conversion mutant protein of the present invention in which any of the 31st and 134th lysine residues is preserved and all other lysine residues are converted to other amino acid residues.
- the lysine-converted mutant protein thus produced is advantageously used in the present invention in which the activity does not disappear even when bound to a water-soluble polymer.
- any one of the amino acid sequences of SEQ ID NOs: 4 to 9 (corresponding to the nucleotide sequences of SEQ ID NOs: 10 to 15 in the sequence listing) is used, respectively. Including. These are shown in Table 1.
- MUT1 is the 145th arginine residue as a leucine residue, the 146th alanine residue as a asparagine residue, and the 149th methionine residue as tyrosine.
- MUT2 is a mutant protein converted to a residue.
- 145th arginine residue is an isoleucine residue and 146th alanine residue is a serine residue.
- MUT3 has the 145th arginine residue as the leucine residue, the 146th alanine residue as the serine residue, and the 149th methione residue.
- MUT4 is a mutant protein in which the 145th arginine residue is the valine residue, and the 46th arginine residue is the mutated amino acid IJ of wild type IFN a 8b. This is a mutated protein in which alanine residues are converted to wasparagine residues and the 149th methionine residue is converted to a thiocin residue.
- MUT2K31 is a lysine conversion mutant protein in which all lysine residues except the 31st lysine residue are converted to other amino acids in the amino acid sequence of “MUT2”.
- this is a lysine conversion mutant protein in which all lysine residues other than the 134th lysine residue have been converted to other amino acids.
- the IFNa mutant protein of the present invention is obtained by amplifying the DNA thus obtained by PCR reaction, if necessary, and then introducing it into a host such as E. coli via a plasmid vector or the like for transformation.
- a desired amount can be obtained by selecting a clone producing the target protein from the transformant and culturing it.
- the culture can be collected, for example, by dialysis, salting out, filtration, concentration, and centrifugation.
- General methods for protein purification such as fractional precipitation, gel filtration chromatography, ion exchange chromatography, hydrophobic chromatography, affinity chromatography, chromatofocusing, gel electrophoresis, and isoelectric focusing should be applied.
- the specific activity of the IFN-mutated protein used in the present invention is usually 2.5 X 10 8 IUZmg protein or more, preferably when applying the bioassay method using the FL cell-sindbis virus system, preferably 3 ⁇ 10 8 IU / mg protein or more, more preferably 3.5 ⁇ 10 8 IU / mg protein or more.
- the bio-assay method using LS 174T cells derived from human colon cancer and vesicular stomatitis virus (VSV) can detect IFN-8 and its mutant proteins with high sensitivity, and the IFNa mutation of the present invention.
- an IFNa mutant protein When the specific activity of an IFNa mutant protein is calculated by this method, it is usually 5 ⁇ 10 8 IUZmg protein or more, preferably 1 ⁇ 10 9 IU / mg protein or more, More preferably, it is 6 ⁇ 10 9 IU / mg protein or more.
- the water-soluble polymer that is artificially bound to the IFNa mutant protein of the present invention is preferably a non-protein that is substantially water-soluble and is harmless to the living body and difficult to become an antigen.
- synthetic polymers such as homopolymers such as polyvinyl alcohol, polyethylene glycol, polyvinyl pyrrolidone, and polypropylene glycol, copolymers of ethylene glycol and vinyl alcohol, propylene glycol, and derivatives thereof are used.
- natural polymers such as erucinan, dextran, hydroxyethyl cellulose, punoleran, and methylcellulose.
- polyethylene glycol homopolymers, Copolymers of cole with other water-soluble polymers and their derivatives are preferred.
- the molecular weight of the water-soluble polymer is usually adjusted to an average molecular weight in the range of 500 to 200,000 daltons, preferably 1,000 to 80,000 daltons. If the molecular weight is uneven, Prior to the protein binding reaction, fractionation is carried out by a general-purpose method such as fractional precipitation or gel filtration chromatography. Although depending on the type of water-soluble polymer and the final use of the IFN a mutant protein, if the molecular weight of the water-soluble polymer is below the above range, it becomes difficult to improve the pharmacokinetics. The physiological activity of the complex may decrease too much and lose its action as a pharmaceutical product.
- the bond formed between the protein moiety and the water-soluble polymer is preferably an amide bond method that forms a stable covalent bond.
- the ratio of the protein and the water-soluble polymer at the start of the reaction is 1: 0.1 to 1: 100, preferably 1: 0.5 to 1 in molar ratio. : 50, most preferably increasing or decreasing in the range of 1: 1 to 1:10. In general, if it is below this range, the efficiency of the binding reaction will decrease. Conversely, if it exceeds this range, the binding reaction will be too early, and it will be difficult to control the number of molecules of the water-soluble polymer that binds to the protein. In any case, the efficiency of the reaction and the purification after the reaction is lowered, and it is usually desirable to adjust in the above range.
- the temperature, pH, and reaction time during the reaction are set so that the IFNa mutant protein is inactivated or difficult to decompose, and unwanted side reactions are minimized.
- pH 0.1 to 12 preferably pH 5 to 10, 0.1 to 50 hours, preferably so that the reaction is completed within 10 hours.
- the bioactive complex thus obtained can be purified by the same method as that for purifying IFNa mutant protein.
- concentration, salting out, centrifugation, freezing can be performed. It is made liquid or solid by a method such as drying.
- the number of water-soluble polymers to be bound to the IFN-mutated protein is usually 1 molecule or more, preferably 1 to 2 molecules, more preferably 1 minute per molecule of IFN-mutated protein. A child.
- the specific activity when the IFN mutant protein of the present invention is used as a physiologically active complex is 3 X 10 6 IU / mg protein or more, preferably 1 X when measured in the FL cell-Sindbis virus system. 10 7 IU / mg protein or more, more preferably 2 ⁇ 10 7 IU / mg protein or more.
- the specific activity measured by the LS I 74T cell ZVSV system derived from human colon cancer is Usually, it is 2 ⁇ 10 7 IU / mg protein or more, preferably 4 ⁇ 10 7 IU / mg protein or more.
- the IFN a mutant protein of the present invention or a physiologically active complex in which it is bound to a water-soluble polymer is extremely useful as a sensitive disease agent for treating or preventing a sensitive disease.
- the term “susceptible disease” as used in the present invention means the ability to administer the sensitive disease agent of the present invention alone or all of the diseases that can be treated or prevented by administration together with other drugs.
- colon cancer rectal cancer, stomach cancer, kidney cancer, thyroid cancer, tongue cancer, bladder cancer, choriocarcinoma, liver cancer, uterine cancer, pharyngeal cancer, lung cancer, breast cancer, malignant melanoma, neuroblastoma, ovarian tumor, Testicular tumor, osteosarcoma, spleen cancer, adrenal gland, goiter, brain tumor, malignant melanoma, solid tumors such as mycosis fungoides, blood system tumors such as leukemia, lymphoma, and also hepatitis B, hepatitis C Virus diseases such as AIDS and SARS, bacterial infections such as Chlamydia, immune diseases such as allergies and rheumatism.
- the sensitive disease agent of the present invention has a wide variety of uses, for example, as an antitumor agent, an antiviral agent, an anti-infective agent, an immunodisease agent, etc., for treating and preventing such a disease.
- the sensitive disease agent of the present invention is administered as a sensitive disease agent of the present invention as a single dose according to the administration route.
- the sensitive disease agent of the present invention includes a so-called drug in a dosage unit form.
- the drug in the dosage unit form refers to the sensitive disease agent of the present invention, for example, at a single dose or Meaning a drug in a physically separate unitary form suitable for dosing, comprising an amount corresponding to an integral multiple (up to 4 times) or a divisor (up to 1Z40).
- examples of such drugs in the dosage unit form include capsules, granules, pills, suppositories, powders, and tablets. , Injections, poultices and the like.
- the sensitive disease agent of the present invention comprises the IFNa mutant protein of the present invention and / or a physiologically active complex in which a water-soluble polymer is bound to them as an active ingredient. It can also be used in combination with a wild type IFN containing IFN-8. Further, for example, it does not preclude blending appropriate preparations commonly used for drugs such as excipients, ointment bases, solubilizers, flavoring agents, flavoring agents, coloring agents, and emulsifiers.
- skin disinfectant for skin, wound protection agent, anti-inflammatory agent, etc. vitamin A agent, vitamin B agent, vitamin C simultaneous lj, vitamin D agent, vitamin Vitamin preparations such as E-form lj, vitamin K preparations, calcium preparations, inorganic preparations, saccharide preparations, organic acid preparations, protein amino acid preparations, organ preparations and other cell tonics such as chlorophyll preparations and pigment preparations, Chemotherapy such as alkylating agents, antimetabolites, antitumor antibiotic preparations, antitumor drugs such as antitumor plant component preparations, allergy drugs such as antihistamines, antituberculosis drugs, synthetic antibacterial drugs, and anti-winoles drugs
- vitamins A agent, vitamin B agent, vitamin C simultaneous lj, vitamin D agent vitamin Vitamin preparations such as E-form lj, vitamin K preparations, calcium preparations, inorganic preparations, saccharide preparations, organic acid preparations, protein amino acid preparations, organ preparations and other cell tonics such as chlorophyll
- the sensitive disease agent of the present invention may be used as an immunological adjuvant, for example, actinomycin D, acegraton, ifosfamide, ubenimetas, etoposide, enocitabine, aclarubicin hydrochloride, idarubicin hydrochloride, irinotecan hydrochloride, epilubicin hydrochloride, gemcitabine hydrochloride, hydrochloric acid Daunorubicin, doxorubicin hydrochloride, nitrogen mustard N-oxide, dimustine hydrochloride, pirarubicin hydrochloride, fuadzol hydrochloride hydrate, bleomycin, brocarbazine hydrochloride, mitoxantrone hydrochloride, carbocon, carboplatin, carmofur, tamoxifen taenate , Toremifene taenoate, krestin, medroxicetate oral guestron
- the IFNa mutant protein of the present invention when allowed to function also as an immune promoter, a synergistically high antitumor effect that cannot be easily achieved with only one of them can be obtained.
- the combined use can reduce the dose of the antitumor drug, and as a result, has the benefit of significantly reducing the side effects caused by the antitumor drug.
- the sensitive disease agent of the present invention exerts an effect on the treatment and prevention of susceptibility diseases, whether applied by the oral route or parenteral route.
- a preparation comprising the IF N mutant protein of the present invention is prepared from 0.01 to 1,000 ⁇ g / kg body weight Z day, preferably 0.1 to 100 ⁇ g / body weight / day, divided into multiple doses as needed from 1 to 7 times / week Force applied by the oral route over a week to 1 year, or by parenteral routes such as intradermal, subcutaneous, intramuscular, intravenous, intranasal, rectal, intraperitoneal.
- the physiologically active complex produced by binding the IFN a mutant protein of the present invention to a water-soluble polymer is stable, hardly decomposed by proteases in blood, etc., and has a wild residence time in the IFN Depending on the route of administration significantly longer than a 8, it can reach 10 times or more, so when applied by the same route for the same sensitive disease, the dose can be significantly reduced. It has the benefit of minimizing side effects caused by cytotoxicity to normal cells.
- Amino acid residues of IFN 8b IJ (Oji IJ table [J No. 2]), amino acid residues 30, 33, 145, 14 6, 149 and 150 are other amino acids.
- chromosomal DNA was collected from a human lymphoblast-derived cell line BALL_1 (JCRB0071: Japanese 'collection'ob'research-bioresources), and this was used as a cocoon and sequenced in the sequence listing.
- This restriction enzyme is transferred to a plasmid vector (trade name “pET_3a”, sold by EMD Biosciences (USA)) having a T7 promoter region, a T7 terminator region, an ampicillin resistance gene region, and a ColEl ′ Ori region. It was introduced into the site.
- pET_3a trade name “pET_3a”, sold by EMD Biosciences (USA)
- pET_3a plasmid vector having a T7 promoter region, a T7 terminator region, an ampicillin resistance gene region, and a ColEl ′ Ori region. It was introduced into the site.
- the DNA region encoding IFN ⁇ 8 was analyzed by a conventional DNA sequencer, the nucleotide sequence of SEQ ID NO: 18 in the sequence listing was decoded, and the DNA was found to be DNA encoding IFN-8b.
- SEQ ID NO: 19 (primer for converting the codons of amino acids 30 and 33 to NNS) and SEQ ID NO: 20 (codons of amino acids 145, 146, 149 and 150 are converted to NNS) PCR is performed according to a conventional method, and the obtained PCR product is converted into a saddle shape to add SEQ ID NO: 21 (primer for adding a restriction enzyme Ncol cleavage site to the 5 'end) and sequence.
- a conventional force S-lay PCR was performed using No. 22 (a primer for adding a restriction enzyme Notl cleavage site to the 3 ′ end).
- helper phage M13K07 Invitrogene Co., Ltd. (Tokyo, Japan) was added at 1 x 10 9 pfu per ml of medium, cultured at 37 ° C for 1 hour with shaking, and centrifuged. After separation, the precipitate was collected, suspended in 2% medium containing 50 ⁇ g / ml kanamycin and 100 ⁇ g / ml ampicillin, and cultured with shaking at 37 ° C. for 6 hours.
- the phage protein bound to IF NAR2 was eluted with 0.1 M hydrochloric acid aqueous solution, collected in a separate container, and neutralized by adding half of 1 M Tris (pH 8.0) of the hydrochloric acid solution.
- the collected phages are infected with E. coli TG-1, and the E. coli is cultured in 2% medium containing 2% (w / v) gnolecose and 100 ⁇ g / ml ampicillin, and then the helper phage is used in the same manner as in Experiment 1-1.
- Ml 3K07 was added to release the phage from the cells.
- DNA encoding the 12 types of mutant proteins in Table 2 was used as a primer with the oligonucleotides of the nucleotide sequences represented by SEQ ID NO: 16 and SEQ ID NO: 17 as primers.
- DNA specific to the primer sequence was amplified by PCR, and then digested with restriction enzymes Ndel and BamHI. This is transferred to a plasmid vector (trade name “pET-3a”, sold by EMD Biosciences (USA)) having a T7 promoter region, a T7 terminator region, an ampicillin resistance gene region, and a ColEl ′ Ori region. It was introduced into the restriction enzyme site.
- This plasmid was introduced into Escherichia coli BL21DE3 strain to obtain wild-type IFN a 8 or Escherichia coli for production of each mutant protein.
- each cell line with RPMI1640 medium containing 10 (v / v)% urine fetal serum at a concentration of 8 X 10 3 to 2 X 10 5 cells / ml.
- each of the above 4 mutants was serially diluted and added in the range of 40 pg to 10 / g / ml, and cultured at 37 ° C. in a 5% carbon dioxide atmosphere for 72 to 120 hours.
- Cell Count Kit-8 (Wako Pure Chemical Industries, Ltd. (Osaka, Japan)) according to conventional methods, and to suppress the growth to half from the measured data.
- the concentration (IC) required for the calculation was calculated.
- IC concentration
- mutant proteins No. 1, 2, 3 and 4 were found to exhibit stronger growth inhibitory activity against a wider variety of cell lines than wild type IFN 8. .
- mutant proteins No. 1, 2, 3 and 4 have a higher cytostatic activity against all cell lines. Power, ivy.
- the obtained Escherichia coli was suspended in 2YT medium containing 2% (wZv) gnoleose, cultured at 37 ° C for 1 hour with shaking, and then 2% (w / v) dalcose and 100 / ig / ml ampicillin were added.
- the LB plate was plated and cultured for 16 hours. All E. coli colonies that appeared on the plate were collected, suspended in 2YT medium containing 2% (w / v) glucose and 100 ⁇ g / ml ampicillin, and cultured at 37 ° C with shaking. At 0.5, add helper phage M13K07 and incubate at 37 ° C for 1 hour with shaking.
- Collect cells by centrifugation and culture medium contains 50 ⁇ g / ml kanamycin and 100 ⁇ g / ml ampicillin.
- phages were produced by shaking culture at 37 ° C for 7 hours to obtain a phage library.
- these were screened by a vanning method using a polyethylene immunotube to which a fusion protein (SEQ ID NO: 24 in the sequence listing) of IFNAR2 and the Fc region of human immunoglobulin G was bound.
- the lysine conversion mutant protein “MUT2K31” (SEQ ID NO: 8 in the sequence listing) in which only the 31st lysine residue was not converted to another amino acid residue, and only the 134th lysine residue was another amino acid residue.
- a lysine-mutated mutant protein “MUT2K134” (SEQ ID NO: 9 in the sequence listing) that was not converted to ⁇ was obtained.
- the amino acid sequence of the IFN hypermutated protein “MUT2” SEQ ID NO: 5 in the Sequence Listing
- the lysine-mutated mutant proteins “MUT2K31” and “MUT2K134” of the IFN a mutant protein have antiviral activity and cellularity compared to the original mutant protein “MUT2”. Although the growth inhibitory activity was decreased, the antiviral activity and cell growth inhibitory activity were higher than those of wild-type IFN a 8.
- Polyethylene glycol having a molecular weight of 20 kDa was bound to the lysine-converted mutant protein obtained by the method of Experiment 2-2 or the wild type IFN a 8 obtained in Experiment 13. Specifically, the wild-type IFN ⁇ 8, IFN ⁇ mutant protein ⁇ MUT2K31 '' or ⁇ MUT2K134 '' is dissolved in a borate buffer solution (pH 9.0) to a concentration of 0.1 to 5 mg / ml, and then dissolved in water. Polyethylene glycol (m-PEG-SPA) activated with monomethoxy N succinimidyl propionate as a polymer is added in a molar ratio of 3 to 8 times the protein, and 2 hours at 7 ° C.
- m-PEG-SPA polyethylene glycol
- the bioactive complex prepared by binding polyethylene dialicol to “MUT2K31” or “MUT2K134” is significantly more than the commercially available IFN a 2a formulation bound to polyethylene glycol. It had high antiviral activity and cytostatic activity.
- IFN a mutant proteins “MUT1,” “MUT2,” “MUT3,” or “MUT4” obtained in Experiment 1-3 were tested on 8-week-old male mice (body weight 20-25 g).
- the lysine-mutated mutant protein MUT2K31 or IFN a mutant protein MUT2 obtained in step 2 Either MUT2K134 or a bioactive complex in which one molecule of polyethylene glycol is bound to MUT2K31 or MUT2K134 obtained in Experiment 3-1, is administered by injection via the transdermal, oral or peritoneal route.
- IFN ct mutant protein “MUT1,” “MUT2,” “MUT3,” or “MUT4” obtained in Experiment 1-3 was added to 100 ml of physiological saline containing 1% (w / v) purified gelatin as a stabilizer.
- This product is useful as a dry injection for treating or preventing sensitive diseases including malignant tumors, viral diseases, bacterial infections and immune diseases.
- the obtained MUT2K31 or MUT2K134 is mixed with an appropriate amount of any of the bioactive complexes in which one molecule of polyethylene glycol is bound, adjusted to pH 7.2, and bioactive per lg.
- a paste containing about 5 zg of the composite was obtained.
- This product excellent in spreadability and stability is useful as an ointment for treating or preventing susceptible diseases including malignant tumors, viral diseases, bacterial infections and immune diseases.
- Anhydrous crystalline ⁇ -maltose powder (registered trademark “Fine Tose”, Hayashibara Shoji Co., Ltd.
- the product with excellent ingestion and stability is useful as a tablet for treating or preventing sensitive diseases including malignant tumors, viral diseases, bacterial infections and immune diseases.
- the IFN a mutant protein of the present invention has significantly higher activity than conventional IFN ⁇ preparations, and when combined with a water-soluble polymer to form a bioactive complex, It is excellent and maintains a high concentration state in blood for a long time even when administered by injection. Therefore, according to the present invention, it is possible to provide a sensitive disease agent superior in anti-winore activity and anti-tumor activity to conventional sensitive disease agents containing IFN as an active ingredient. In the field, for example, it has a wide variety of uses as an antitumor agent, an antiviral disease agent, an anti-infective agent, an immune disease agent and the like.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05806220A EP1842857B1 (en) | 2004-11-12 | 2005-11-09 | Mutant interferon proteins and use thereof |
CA002587369A CA2587369A1 (en) | 2004-11-12 | 2005-11-09 | Mutant interferon .alpha. proteins and use thereof |
DE602005026869T DE602005026869D1 (de) | 2004-11-12 | 2005-11-09 | Interferonproteinmutanten und deren anwendung |
JP2006544910A JP4815356B2 (ja) | 2004-11-12 | 2005-11-09 | インターフェロンα変異蛋白質とその用途 |
US11/719,283 US7666403B2 (en) | 2004-11-12 | 2005-11-09 | Mutant interferon α protein and use thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004-329461 | 2004-11-12 | ||
JP2004329461 | 2004-11-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006051805A1 true WO2006051805A1 (ja) | 2006-05-18 |
Family
ID=36336482
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/020514 WO2006051805A1 (ja) | 2004-11-12 | 2005-11-09 | インターフェロンα変異蛋白質とその用途 |
Country Status (6)
Country | Link |
---|---|
US (1) | US7666403B2 (ja) |
EP (1) | EP1842857B1 (ja) |
JP (1) | JP4815356B2 (ja) |
CA (1) | CA2587369A1 (ja) |
DE (1) | DE602005026869D1 (ja) |
WO (1) | WO2006051805A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009116491A1 (ja) | 2008-03-21 | 2009-09-24 | 株式会社林原生物化学研究所 | ヒトインターフェロンαサブタイプα8及びその変異蛋白質を特異的に認識するモノクローナル抗体 |
JP2020010697A (ja) * | 2011-10-28 | 2020-01-23 | テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド | ポリペプチド構築物およびその使用 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104056254A (zh) * | 2013-03-18 | 2014-09-24 | 赛德医药科技股份有限公司 | 用以降低肝炎病患复发率的组合物 |
WO2022079205A1 (en) * | 2020-10-15 | 2022-04-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of ifn-alpha polypeptides for the treatment of coronavirus infections |
-
2005
- 2005-11-09 EP EP05806220A patent/EP1842857B1/en not_active Expired - Fee Related
- 2005-11-09 CA CA002587369A patent/CA2587369A1/en not_active Abandoned
- 2005-11-09 WO PCT/JP2005/020514 patent/WO2006051805A1/ja active Application Filing
- 2005-11-09 JP JP2006544910A patent/JP4815356B2/ja not_active Expired - Fee Related
- 2005-11-09 DE DE602005026869T patent/DE602005026869D1/de active Active
- 2005-11-09 US US11/719,283 patent/US7666403B2/en not_active Expired - Fee Related
Non-Patent Citations (4)
Title |
---|
PIEHLER J. ET AL: "New structural and functional aspects of the type I interferon-receptor interaction revealed by comprehensive mutational analysis of the binding interface", J.BIOL.CHEM., vol. 275, no. 51, 2000, pages 404725 - 40433, XP003007341 * |
TSUTSUMI Y. ET AL: "Iyaku Kachi ni Sugureta Kinosei Jinko Tanpakushitsu ni Morateki Katsu Jinsoku Dotei System to Proteome Soyaku heno Tenkai", CELL TECHNOLOGY, vol. 22, no. 8, 2003, pages 873 - 881, XP003007342 * |
YAMAMOTO Y. ET AL: "Site-specific PEGylation of a lysine-deficient TNF-alpha with full bioactivity", NAT.BIOTECHNOL., vol. 21, no. 5, 2003, pages 546 - 552, XP003007344 * |
YOSHIOKA Y.: "Iyaku Kachi ni Sugureta Kinosei Tanpakushitsu no Morateki Sakusei to Sono DDS heno Oyo", JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, vol. 124, no. 8, August 2004 (2004-08-01), pages 531 - 539, XP003007343 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009116491A1 (ja) | 2008-03-21 | 2009-09-24 | 株式会社林原生物化学研究所 | ヒトインターフェロンαサブタイプα8及びその変異蛋白質を特異的に認識するモノクローナル抗体 |
JPWO2009116491A1 (ja) * | 2008-03-21 | 2011-07-21 | 株式会社林原生物化学研究所 | ヒトインターフェロンαサブタイプα8及びその変異蛋白質を特異的に認識するモノクローナル抗体 |
US8357782B2 (en) | 2008-03-21 | 2013-01-22 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Monoclonal antibodies specific for human interferon-alpha subtype alpha 8 |
JP2020010697A (ja) * | 2011-10-28 | 2020-01-23 | テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド | ポリペプチド構築物およびその使用 |
Also Published As
Publication number | Publication date |
---|---|
EP1842857B1 (en) | 2011-03-09 |
US7666403B2 (en) | 2010-02-23 |
EP1842857A4 (en) | 2008-10-08 |
JP4815356B2 (ja) | 2011-11-16 |
JPWO2006051805A1 (ja) | 2008-05-29 |
DE602005026869D1 (de) | 2011-04-21 |
EP1842857A1 (en) | 2007-10-10 |
US20090311218A1 (en) | 2009-12-17 |
CA2587369A1 (en) | 2006-05-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5366161B2 (ja) | Tnfアンタゴニスト及びそれを有効成分とするtnf阻害剤 | |
US7504237B2 (en) | Polynucleotides encoding interferon gamma polypeptides | |
JP4815356B2 (ja) | インターフェロンα変異蛋白質とその用途 | |
WO2023070056A2 (en) | Heterodimeric fc cytokines and uses thereof | |
EP1354893B1 (en) | Physiologically active complex with TNF activity | |
US7179891B2 (en) | Physiologically active complex | |
JP4866612B2 (ja) | 生理活性複合体 | |
RU2797536C2 (ru) | Варианты интерлейкина-18 и способы их применения | |
AU782635B2 (en) | Interferon gamma conjugates | |
AU2022229900A1 (en) | Combination therapies with sirp alpha-based chimeric proteins | |
AU2022369312A1 (en) | Heterodimeric fc cytokines and uses thereof | |
CN117355336A (zh) | 基于SIRP α的嵌合蛋白的联合疗法 | |
CN101172160A (zh) | 干扰素γ偶联物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2587369 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006544910 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11719283 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005806220 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2005806220 Country of ref document: EP |